Medicaid Didn’t Count Her $100,000 Stock Portfolio. Cashing Out Its AI Gains Could Threaten Her Coverage

Selling a winning stock can cost nothing in federal taxes yet still wipe out Medicaid coverage, and the calculation turns on a detail most policyholders never think to check before they click sell.

Published October 29, 2026, 6:30am ET · 4 min read

The Full Benefits Desk desk. Editor: Gerelyn Terzo.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

A woman with grey curly hair and glasses, wearing a dark blue sweater, sits at a white desk. She holds white papers in both hands, appearing to review them, with a silver laptop open in front of her. A light beige coffee mug is visible on the desk to her right, and a blurred bright living room with a sofa and a potted plant is in the background.
A woman carefully reviews financial documents and works on her laptop, illustrating the precise attention needed when managing investments that could impact Medicaid eligibility. © insta_photos / Shutterstock.com

Medicaid’s income test for working-age adults never looks at the brokerage statement. A 60-year-old can hold a $100,000 stock portfolio and keep her coverage, because MAGI-based Medicaid, the version that covers most adults under 65, applies no asset test. The danger shows up the day she sells a big winner.

Medicaid’s own MAGI training material lists net capital gains (profit after subtracting capital losses) among the taxable income that counts. A paper gain stays invisible to the eligibility test. Once she sells, the profit goes into the same income math as a paycheck.

Plenty of older investors face this right now. Households ages 55 to 69 held 39.3% of the household sector’s stocks and mutual fund shares outside workplace retirement plans in the second quarter of 2026. The value of those holdings rose 24.9% from a year earlier, according to Federal Reserve distributional data.

Why a $100,000 Portfolio Never Counted Against Her

Picture a hypothetical woman, age 60, who lives in a Medicaid expansion state and makes $18,000 a year from part-time work. She’s an illustration, but her setup is common. Her $100,000 portfolio leans heavily on AI stocks that have run up.

She’s still several years from Medicare, the federal health program that starts at 65. Her coverage comes from Medicaid, a joint effort of the federal and state governments for those with low incomes. Federal guidance for states says no resource test is applied to eligibility groups that use MAGI-based methodologies. Nursing-home Medicaid works under a separate, asset-tested rules, and families who mix up the two often panic over the wrong number.

For expansion adults, the income ceiling is 138% of the federal poverty level. The 2026 poverty guideline for one person in the 48 contiguous states is $15,960, which puts her limit at $22,024.80 a year, or about $1,835 a month. Her wages fit under it easily.

How a $40,000 AI Gain Becomes Countable Income

Now say she sells AI shares worth $70,000 that she bought for $30,000. The sale produces a $40,000 taxable gain. Medicaid counts that gain, and the rest of the proceeds stay out of the calculation. The tax code treats gains derived from dealings in property as gross income, and Treasury rules set an investment’s basis as the cost thereof. The $30,000 she originally put in is her cost basis and is not treated as new income.

Her net worth barely changes because she simply traded stock for cash. Her countable income for the year jumps from $18,000 to $58,000, well past the ceiling.

She also can’t sell the shares now and report that same gain little by little over future years. Publicly traded stock doesn’t qualify for installment-sale treatment, so the gain from a sale lands in the year she makes it. She can, however, choose to sell only part of the position now and leave the rest for another year.

Her federal tax bill could be tiny. For 2026, the 0% long-term capital gains rate covers single filers’ taxable income up to $49,450. A gain taxed at 0% still counts in full toward Medicaid, so a sale that costs nothing in tax can still cost her the coverage.

Losses help. Medicaid counts net gains, so selling a losing position in the same tax year reduces the number. Cost basis matters too, and shares bought at higher prices produce smaller gains for the same sale.

Monthly or Annual Income: Your State Decides How the Gain Hits

Federal Medicaid rules give states some flexibility in how they measure income. New applicants are generally judged on current monthly household income. For people already enrolled, states can use either current monthly income or projected annual household income and family size for the remainder of the calendar year. They can also adopt a reasonable method to account for expected changes in income.

That choice changes how the sale plays out. In a monthly-income state, a $40,000 gain blows past a roughly $1,835 monthly limit in the month of the sale. In a state that projects annual income, the gain could lift her full-year figure above $22,024.80. Some states handle irregular income over a longer window, so her state Medicaid agency’s written policy determines which test applies to her.

Run Two Numbers Before Clicking Sell

Careful sellers figure the tax on the gain and the Medicaid income effect side by side, for the month and the year of the sale. Splitting sales across calendar years, matching winners with losers, or selling higher-basis shares first can all reduce the countable gain.

Timing helps most. Medicaid and Medicare use very different income rules. Under 2026 Medicare brackets, a single filer doesn’t face the Part B income surcharge until modified adjusted gross income exceeds $109,000. So the same kind of gain that can create a Medicaid problem at 60 may not create an IRMAA problem once she’s on Medicare (IRMAA is one of several Medicare surcharges that catch retirees off guard, and we mapped the rest in a free guide here: Medicare’s Hidden Bills).

Contact [email protected] for any questions or corrections.

Gerelyn Terzo

Gerelyn Terzo is the author of dividend investing handbook "Dividend Investing Strategies: How to Have Your Cake & Eat It Too." A veteran financial journalist, she covers agri-finance for outlets like Global AgInvesting and the broader stock market and personal finance for 24/7 Wall Street. She began at CNBC and later helped launch Fox Business in New York. Gerelyn currently resides in Woodland Park, Colorado and dabbles in nature photography as a hobby.

All articles →